Value Microcaps Free-For-All

[zenvesting]

BLLI: This stent patent application makes BLLI a potential zip code changer IMO.

Here's some excerpts from the recent patent application of theirs:

Surgical stent having micro-geometric patterned surface

1) Abstract text: A surgical stent having thereon micro-geometric patterned surface and the method of use for inhibiting smooth muscle cell growth into stent lumen are disclosed. The surgical stent has a generally cylindrical stent frame configured to be implanted into a body lumen, and the stent frame has thereon a micro-geometric patterned surface which includes a multiplicity of microgrooves distributed in a predetermined pattern. Each of the microgrooves has a width in a range of from about 4 to about 40 microns and a depth in a range of from about 4 to about 40 microns. The surgical stent can further include drug wells, and the surgical stent can have a biocompatible chemical compound, such as thrombosis inhibitor or cell growth inhibitor, embedded in the microgrooves or drug wells.

2) The present invention relates to a surgical stent for implantation into a body lumen, such as an artery. More specifically, the present invention relates to a surgical stent which has a micro-geometric patterned surface on the stent frame to inhibit smooth muscle cell growth in the stent lumen and to reduce in-stent restenosis.

3) .....it is apparent that there remains the need of improving the existing drug-eluting stents, and developing alternative designs and methods for inhibiting smooth muscle cell proliferation to reduce in-stent restenosis.

4) With any one of the above-described configurations, the micro-geometric patterned drug eluting stents have double benefit of the chemical inhibition and geometric inhibition on the proliferation of smooth muscle cells. It should be understood that the current drug eluting stent releases its surface coated drug in a short period of time, i.e., in days. Therefore, after the complete release of the coated drug, there is no mechanism to prevent growth of the smooth muscle cell into the stent lumen. With the micro-geometric patterned drug eluting stent of the present invention, the patient not only can be benefited by an immediate chemical inhibition of thrombosis and restenosis caused by the surgical disturbances, the patient can also have a long term benefit of geometric inhibition provided by the micro-geometric patterned surface on the surgical stent. Furthermore, because of the presence of the geometric inhibition mechanism, one can reduce the amount of drug coated on the stent surface, which can reduce potential negative response of the patient to the drug.

5) As described previously, an improved surgical stent which reduces in-stent restenosis has been a long felt need in the medical field. The present invention is the first to provide a geometric inhibition mechanism by incorporating micro-geometric patterns on to the stent surface, thereby inhibiting smooth muscle cell growth into the stent lumen.



>>These guys who financed BLLI earlier this year could be a big help in getting this technology some attention from the big players in this field:
http://www.radiusventures.com/healthcare_industry.asp

Notice that Radius Ventures has previously sold a company to Boston Scientific....and they also have an investment in CONR. Do you think it's a coinsidence that this stent patent application was filed the same day Radius financed BLLI?

But BLLI doesn't do much PR, so you may not hear anything from them about this until there's something real to report about it?

But in the mean time...and at this price....the growth in their core dental implant business could keep them moving up with each quarter's numbers.

...and again, they don't talk about that much either, but they're working hard at increasing market exposure and sales of their dental implants too:
http://www.biolok.com/index.mv?pg=calendar/shows